Wall Street's new favorite, AMGN.US (AMGN.US) reinvigorates: lung cancer drug Imdelltra approved to set off a new engine of growth

The Zhitong Finance App learned that the US Food and Drug Administration (FDA) announced a major approval on Thursday, bringing new hope to lung cancer patients: Amgen (AMGN.US) Imdelltra (generic name tarlatamab) was approved as a second-line treatment for advanced small cell lung cancer (SCLC). This decision means that Imdelltra will be the new option for patients as their cancer continues to progress after receiving other treatments (usually chemotherapy). It is understood that Imdelltra's approval is based on its performance in clinical trials. These trials

Zhitong Finance44minutes ago

Amgen Gets FDA Approval for Small-cell Lung-cancer Treatment

By Ben Glickman Amgen (AMGN) on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer. The pharmaceutical company said that Imdelltra, an immunothera

MarketWatch20:22 ET

Express News | FDA Approves Imdelltra™ (Tarlatamab-Dlle), the First and Only T-Cell Engager Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer

Reuters18:46 ET

FDA APPROVES IMDELLTRA (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

PR Newswire18:46 ET

Express News | Amgen Says Imdelltra Will Be Available at the U.S. List Price of $31,500 in Cycle 1 and $30,000 per Cycle Thereafter

Reuters16:21 ET

Express News | US FDA Approves Amgen's Lung Cancer Treatment Imdelltra for Treatment of Adult Patients With Extensive Stage Small Cell Lung Cancer

Reuters15:23 ET